Eosinophilic Esophagitis– Pipeline Review, 2019

We will customize the report to meet your research goals, helping you gain a competitive edge, and make informed decisions.

Schedule a 30 minutes session to understand our consulting capabilities – SCHEDULE NOW

Table of Content:

1.Introduction

1.1. Report Overview

2.Eosinophilic Esophagitis- Overview

3. ExecutiveSummary

4.Eosinophilic Esophagitis: Pipeline Assessment

4.1. By Stage of Development

4.2. By Route of Administration

4.3. By Drug Class

4.4. By Molecule Type

4.5. By Therapy Area / Indication

4.6. By Drug Target

4.7. By Sponsor

5. EosinophilicEsophagitis: Company & Drug Profiles

5.1. Clinical Stage

5.1.1.APT-1011 – Adare Pharmaceuticals, Inc.

5.1.1.1.Company Overview

5.1.1.2.Product Description

5.1.1.3.R&D Status & Development Activities

5.1.1.4.Mechanism of Action

5.1.1.5. MoleculeType

5.1.1.6. Stageof Development

5.1.1.7.Indications

5.1.1.8. Routeof Administration

5.1.1.9.Funding

5.1.2. AK002 –Allakos Inc.

5.1.2.1.Company Overview

5.1.2.2.Product Description

5.1.2.3.R&D Status & Development Activities

5.1.2.4. Mechanismof Action

5.1.2.5.Molecule Type

5.1.2.6. Stageof Development

          5.1.2.7.Indications

5.1.2.8. Routeof Administration

5.1.2.9.Funding

5.1.3. SHP621– Shire

5.1.3.1.Company Overview

5.1.3.2.Product Description

5.1.3.3.R&D Status & Development Activities

5.1.3.4.Mechanism of Action

5.1.3.5.Molecule Type

5.1.3.6. Stageof Development

5.1.3.7.Indications

5.1.3.8. Routeof Administration

5.1.3.9.Funding

5.1.4. Others

5.2. Preclinical

5.2.1. CompanyOverview

5.2.2. ProductDescription

5.2.3. R&DStatus & Development Activities

5.2.4. Mechanismof Action

5.2.5.Molecule Type

5.2.6.Indications

5.2.7. Routeof Administration

5.2.8. Funding

6.Eosinophilic Esophagitis: An Overview on Dormant & Discontinued PipelineCandidates

6.1. Overview

6.2. Product Description

6.3. Reason for Discontinuation

7.Eosinophilic Esophagitis: Additional Key Insights

7.1.Epidemiology Overview: Eosinophilic Esophagitis

7.2. Current Market Scenario: Eosinophilic EsophagitisTherapeutics

8.Eosinophilic Esophagitis: News, Press Releases and Conference Details

Note:

1) This Table of Content is tentative and subject to change as the research progresses.

2) Please note that the drug candidates included as examples were in the pipeline when this TOC was designed and their status might have changed since then.